ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.595,74
-0,48%
S&P 500
5.306,04
0,02%
Dow Jones
38.852,86
-0,55%
Euro vs US Dollar
1,08379
-0,14%
Bitcoin
67.855,77
-0,64%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. ARYA Sciences Acquisition Corporation IV (ARYD)

  7. ARYA Sciences Acquisition Corporation IV (ARYD) News

ARYD

ARYA Sciences Acquisitio... (ARYD)

ARYA Sciences Acquisition Corporation IV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ARYD
DatumZeitQuelleÜberschriftSymbolFirma
21/05/202403h31Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:ARYDARYA Sciences Acquisition Corporation IV
20/05/202423h25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARYDARYA Sciences Acquisition Corporation IV
16/05/202422h41Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
16/05/202422h15Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
06/05/202412h25GlobeNewswire Inc.Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd WiderNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
28/02/202423h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
28/02/202423h02Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
26/02/202422h48Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
26/02/202422h46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
15/02/202422h34Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
15/02/202422h33Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
14/02/202422h16Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
14/02/202422h15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ARYDARYA Sciences Acquisition Corporation IV
14/02/202414h51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
14/02/202412h29PR Newswire (US)Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation TechnologiesNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
14/02/202412h06PR Newswire (US)Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation TechnologiesNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
09/02/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
02/02/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
01/02/202423h08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
30/01/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
22/01/202423h20Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
02/01/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
04/12/202313h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
09/11/202322h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARYDARYA Sciences Acquisition Corporation IV
02/11/202321h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
02/10/202323h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
27/09/202322h47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
05/09/202312h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
11/08/202322h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARYDARYA Sciences Acquisition Corporation IV
02/08/202322h50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
 Showing the most relevant articles for your search:NASDAQ:ARYD

Kürzlich von Ihnen besucht

LSE
BT42
London Card.27f
BIT
UC1C56
Unicredit Bank
POLO
SPONGEUSDT
SpongeBob
NYSE
CFN.L
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten